Log In
BCIQ
Print this Print this
 

INCSHR1210, SHR-1210

  Manage Alerts
Collapse Summary General Information
Company Jiangsu Hengrui Medicine Co. Ltd.
Description mAb against programmed cell death 1 (PDCD1; PD-1; CD279)
Molecular Target Programmed cell death 1 (PD-1) (PDCD1) (CD279)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced solid tumors
Regulatory Designation
PartnerIncyte Corp.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$795.0M

$25.0M

$770.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/02/2015

$795.0M

$25.0M

$770.0M

Get a free BioCentury trial today